RxDoctor Payments Data

Dialyn Soto-Barreto, MD

Geriatric Medicine · Tucker, GANPI 1407006810

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $654 and has fallen 69.5% since, to $199 in 2023.

$1,751in general payments, 2019–2025

Across 114 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$406
  • AstraZeneca$264
  • Takeda Pharmaceuticals U.S.A., Inc.$172
  • Lilly USA, LLC$146
  • AbbVie$134
  • Amgen$97
  • plus $531 from 11 others

What the payments were for

  • Food & beverage$1,751100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,751 in reported general payments places this provider in the 75th percentile of 75 geriatric medicine providers in Georgia.

See all geriatric medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$24,758
Medicare patients
104
Services billed
317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$44,167
JardianceEmpagliflozin15$14,763
EliquisApixaban12$13,151
FarxigaDapagliflozin Propanediol13$10,489
Novolog FlexpenInsulin Aspart11$1,597
Atorvastatin Calcium153$1,137
Albuterol Sulfate HfaAlbuterol Sulfate18$834
Levothyroxine Sodium69$654
Gabapentin52$587
Losartan Potassium50$527
Memantine Hcl22$507
Amlodipine Besylate85$343
Montelukast Sodium17$343
Pregabalin19$323
Mirtazapine15$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$406$44,16733 claims
Boehringer IngelheimJardiance$56$14,76315 claims
PfizerEliquis$85$13,15112 claims
AstraZenecaFarxiga$264$10,48913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 75 geriatric medicine providers in Georgia.

Other geriatric medicine in Tucker

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →